顺铂和血管内皮生长因子受体单抗对荷Lewis瘤小鼠联合治疗的实验研究

Experimental study on antitumor effect of vascular endothelial growth factor receptor-monoclonal antibody combined with cisplatin

目的:观察血管内皮生子因子受体单抗和顺铂联合应用治疗荷Lewis瘤小鼠的疗效。方法:将32只C57BL小鼠分成4组(对照组、顺铂组、血管内皮生长因子受体单抗组、血管内皮生长因子受体单抗联合顺铂组),实验结束后分别处死荷Lewis瘤小鼠,测量肿瘤的长、短径,称取瘤重,计算肿瘤体积、抑瘤率,对有肺转移瘤的小鼠进行计数并作肿瘤的病理检查。结果:血管内皮生长因子受体单抗联合顺铂组有明显的抑瘤作用,抑瘤率为78.44％,明显高于顺铂组(40.01％)和血管肉皮生长因子受体单抗组(56.22％);血管内皮生长因子受体单抗联合顺铂组有肺转移瘤的鼠数为2只,明显少于顺铂组(6只)和血管内皮生长因子受体单抗组(5只)。结论:血管内皮生长因子受体单抗和顺铂有良好的协同抗肿瘤作用,可提高疗效,为临床应用提供了科学依据。

Objective:To investigate the antitumor effect of VEGFR-Ab in combination to cisplatin in treating Lewis tumor bearing mice. Methods: Thirty-two Lewis tumor bearing mice were divided into 4 groups: control group, cisplatin group, VEGFR-Ab group and VEGFR-Ab combined with cisplatin group. Tumor girth, and weight were measured, tumor growth inhibition rates were calculated and lung metastases of the mice were counted. Results:The rate of tumor growth inhibition in the combination group(78. 44%)was significantly higher than that of VEGFR-Ab group alone and cisplatin alone group(56. 22% and 40. 01% respectively, P<0. 05). The number of mice with lung metastasis was 2 in combination group, less than that of VEGFR-Ab group(n=5) and cisplatin group (n=5). Concludsion:The results indicate that there existed synergistic action between VEGFR-Ab and cisplatin.